MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2025. Key highlights include: (CAD)Q3 2025% Change vs.Q3 2024YTD 2025% Change vs.YTD 2024Trailing Twelve Months (TTM) Sept 30, 2025% Change vs.TTM Sept 30, 2024Canadian Pharma Sales9,864,254+19%28,351,130+16%<td style="border-right: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-ali ...